BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Biological: Nivolumab
Biological: Ipilimumab
Drug: IDO1 Inhibitor
Biological: Relatlimab
Biological: Cabiralizumab
Radiation: Radiation Therapy

First Posted Date: 2017-11-07

Last Posted Date: 2022-09-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20

Registration Number: NCT03335540

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Local Institution - 0001, Chicago, Illinois, United States
🇺🇸
Local Institution - 0003, Pittsburgh, Pennsylvania, United States

and more 1 locations

The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis

Interventions: Other: Non-interventional

First Posted Date: 2017-11-06

Last Posted Date: 2022-07-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 265

Registration Number: NCT03331393

Locations: 🇺🇸
Local Institution, Richland, Washington, United States
🇺🇸
Medication Management, LLC, Greensboro, North Carolina, United States
🇺🇸
Local Institution - 0005, Gainesville, Georgia, United States

and more 1 locations

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

Phase 3

Completed

Conditions: Melanoma
Skin Cancer

Interventions: Drug: BMS-986205
Biological: Nivolumab
Drug: Placebo

First Posted Date: 2017-11-06

Last Posted Date: 2021-07-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20

Registration Number: NCT03329846

Locations: 🇺🇸
Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
University Of Chicago, Chicago, Illinois, United States
🇺🇸
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States

and more 16 locations

A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

Phase 1

Terminated

Conditions: Rheumatoid Arthritis
Psoriasis
Ankylosing Spondylitis
Inflammatory Bowel Diseases
Nonalcoholic Steatohepatitis

Interventions: Drug: BMS-986251
Other: Placebo

First Posted Date: 2017-11-06

Last Posted Date: 2019-10-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 38

Registration Number: NCT03329885

Locations: 🇳🇱
Local Institution, Groningen, Netherlands

A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney Function

Phase 1

Completed

Conditions: Cardiac Failure
Myocardial Failure
Congestive Heart Failure
Kidney Failure
Renal Failure

Interventions: Drug: BMS-986231

First Posted Date: 2017-11-06

Last Posted Date: 2019-09-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 48

Registration Number: NCT03332186

Locations: 🇨🇿
Local Institution, Praha 7, Czechia
🇵🇱
Samodzielny Publiczny Secjalistyczny Szpital Zachodni im. sw. Jana Pawla II, Grodzisk Mazowiecki, Poland
🇵🇱
Specjalistyczne Centrum Medyczne Panacea Poznan, Krakow, Poland

Screening for Atrial Fibrillation (AF)-Potential Patients to Increase AF Detection Rate

Completed

Conditions: Atrial Fibrillation

Interventions: Other: Non-interventional

First Posted Date: 2017-10-18

Last Posted Date: 2019-08-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1316

Registration Number: NCT03313167

Locations: 🇯🇵
Local Institution, Itabashi-ku, Tokyo, Japan

An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BMS-986205

First Posted Date: 2017-10-17

Last Posted Date: 2018-01-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT03312426

Locations: 🇺🇸
PPD Austin Clinic, Austin, Texas, United States

A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction

Phase 1

Terminated

Conditions: Heart Failure

Interventions: Drug: Placebo
Drug: BMS-986224

First Posted Date: 2017-09-13

Last Posted Date: 2021-02-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 199

Registration Number: NCT03281122

Locations: 🇨🇿
Vseobecna Fakultni Nemocnice v Praze, Praha 2, Czechia
🇨🇿
Krajska zdravotni - Masarykova nemocnice v Usti nad Labem, Usti nad Labem, Czechia
🇪🇸
Hospital Universitario Ramon Y Cajal, Madrid, Spain

and more 15 locations

Comparing the Effectiveness of a Treat-to-target (T2T) Disease Management Strategy vs. Routine Care (RC) in Adult Patients With Moderate to Severe Rheumatoid Arthritis (RA) Treated With Subcutaneous Abatacept (Orencia - SC)

Completed

Conditions: Rheumatoid Arthritis

Interventions: Other: Non-Interventional

First Posted Date: 2017-09-06

Last Posted Date: 2019-01-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 281

Registration Number: NCT03274141

Locations: 🇨🇦
Local Institution, Westmount, Quebec, Canada

A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan

Completed

Conditions: Non-Small Cell Lung Cancer

First Posted Date: 2017-09-06

Last Posted Date: 2022-02-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 939

Registration Number: NCT03273790

Locations: 🇯🇵
Local Institution, Minato-ku, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy